financetom
Business
financetom
/
Business
/
Trump says he'll nominate Bill Pulte to run Fannie, Freddie regulator
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Trump says he'll nominate Bill Pulte to run Fannie, Freddie regulator
Jan 16, 2025 9:48 AM

Jan 16 (Reuters) - U.S. President-elect Donald Trump

said on Thursday he would nominate Bill Pulte to be the next

director of the Federal Housing Finance Agency (FHFA).

"Bill needs no formal introduction to the Great Citizens of

our Country, because they have seen, and many have experienced,

his philanthropy firsthand," Trump wrote in a post on Truth

Social.

The FHFA regulates Fannie Mae and Freddie Mac, the mortgage

giants that have operated under U.S. government control since

2008. The regulator is expected to play a central role in any

effort to return the pair, which back the majority of the

nation's residential mortgages, to the private sector.

The Trump administration is expected to make ending the

longrunning conservatorship of the pair a priority, after taking

some steps to move them away from government control in his

first term. The current FHFA head, Sandra Thompson, plans to

retire on January 19, one day before Trump's inauguration.

Fannie and Freddie were created by the Congress in 1938

and 1970, respectively, to expand the secondary mortgage market

and promote homeownership by providing access to easy financing.

By packaging mortgages into interest-paying securities

that they then sold to investors, Fannie and Freddie helped

expand the secondary mortgage market and enhance the pool of

capital available for housing. But the subprime mortgage crisis

weighed on their finances, and ultimately led to a government

takeover of the pair that has persisted.

Pulte is a private equity executive and the grandson of

William Pulte, the founder and chairman of U.S. homebuilder

PulteGroup ( PHM ). He also is known for his philanthropic work via

social media. He used the X platform, where he has 3 million

followers, to distribute personal funds and raise money for

people in need.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation
Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation
Feb 5, 2025
10:43 AM EST, 02/05/2025 (MT Newswires) -- Acrivon Therapeutics ( ACRV ) said Wednesday the US Food and Drug Administration has granted its ACR-368 OncoSignature Assay Breakthrough Device designation. The assay is designed to identify endometrial cancer patients who are likely to respond to the company's ACR-368 treatment, the company said. The designation accelerates the product's development, assessment, and review...
Xometry Names Vaidyanathan Raghavan as Chief Technology Officer
Xometry Names Vaidyanathan Raghavan as Chief Technology Officer
Feb 5, 2025
10:51 AM EST, 02/05/2025 (MT Newswires) -- Xometry ( XMTR ) has appointed Vaidyanathan Raghavan as chief technology officer, starting Wednesday, succeeding Matt Leibel who is leaving the company. Leibel's separation from the company was amicable, it said in a filing to the US Securities and Exchange Commission. Leibel will stay on as an employee until Feb. 28 to assist...
Valneva Gets Marketing Authorization in UK for Chikungunya Vaccine; Shares Rise
Valneva Gets Marketing Authorization in UK for Chikungunya Vaccine; Shares Rise
Feb 5, 2025
10:52 AM EST, 02/05/2025 (MT Newswires) -- Valneva (VALN) secured marketing authorization in the UK for its Ixchiq vaccine for chikungunya, a mosquito-borne viral disease. The vaccine, manufactured at the company's leading production site in Livingston, Scotland, got the approval from the Medicines and Healthcare products Regulatory Agency, The single-dose vaccine is for active immunization for the prevention of disease...
Nuvectis Pharma Prices $13.5 Million Public Offering of Shares
Nuvectis Pharma Prices $13.5 Million Public Offering of Shares
Feb 5, 2025
10:51 AM EST, 02/05/2025 (MT Newswires) -- Nuvectis Pharma ( NVCT ) said Wednesday it has priced an underwritten public offering of 2.7 million of its shares at $5.00 apiece to raise $13.5 million. Nuvectis said it has also granted its underwriter a 30-day option to buy up to 405,000 additional shares. It expects to close the offering Feb. 6,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved